Primary Open Angle Glaucoma

Ophthalmology
8
Pipeline Programs
9
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
5
0
1
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
2 programs
1
brinzolamide 1.0%Phase 41 trial
CyPass Micro-StentN/A1 trial
Active Trials
NCT04629521Completed54Est. Apr 2023
NCT00300079CompletedEst. Sep 2007
Thea Pharma
Thea PharmaMA - Waltham
2 programs
1
1
MonoprostPhase 41 trial
T2345Phase 21 trial
Active Trials
NCT01494753CompletedEst. Dec 2008
NCT02017327CompletedEst. Jul 2016
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
XEN63 Glaucoma Treatment SystemPhase 31 trial
Active Trials
NCT06822738Recruiting130Est. Nov 2028
S
SantenCA - Emeryville
2 programs
1
DE-126 Ophthalmic Solution 0.002% QDPhase 21 trial
Microshunt XIN/A1 trial
Active Trials
NCT07235592Not Yet Recruiting112Est. Apr 2027
NCT04742283Completed323Est. Dec 2021
Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
2
PF-03187207Phase 21 trial
PF-03187207 and Latanoprost VehiclePhase 21 trial
Active Trials
NCT00595101Completed117Est. Jun 2008
NCT00441883Completed176Est. Jul 2008
Skye Bioscience
Skye BioscienceSAN DIEGO, CA
1 program
1
SBI-100 Ophthalmic Emulsion, 0.5%Phase 21 trial
Active Trials
NCT06144918Completed56Est. Feb 2024
Glaukos
GlaukosALISO VIEJO, CA
1 program
iStentN/A1 trial
Active Trials
NCT01841450UnknownEst. Nov 2021
Pfizer
PfizerNEW YORK, NY
1 program
prednisolone 1%N/A1 trial
Active Trials
NCT00485108Completed120Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Thea PharmaMonoprost
Alconbrinzolamide 1.0%
AbbVieXEN63 Glaucoma Treatment System
Skye BioscienceSBI-100 Ophthalmic Emulsion, 0.5%
SantenDE-126 Ophthalmic Solution 0.002% QD
Thea PharmaT2345
Bausch + LombPF-03187207
Bausch + LombPF-03187207 and Latanoprost Vehicle
SantenMicroshunt XI
AlconCyPass Micro-Stent
GlaukosiStent
Pfizerprednisolone 1%

Clinical Trials (12)

Total enrollment: 1,088 patients across 12 trials

NCT02017327Thea PharmaMonoprost

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

Start: Dec 2013Est. completion: Jul 2016
Phase 4Completed
NCT00300079Alconbrinzolamide 1.0%

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

Start: Sep 2006Est. completion: Sep 2007
Phase 4Completed
NCT06822738AbbVieXEN63 Glaucoma Treatment System

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

Start: Feb 2025Est. completion: Nov 2028130 patients
Phase 3Recruiting
NCT06144918Skye BioscienceSBI-100 Ophthalmic Emulsion, 0.5%

Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure

Start: Nov 2023Est. completion: Feb 202456 patients
Phase 2Completed
NCT04742283SantenDE-126 Ophthalmic Solution 0.002% QD

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Start: Dec 2020Est. completion: Dec 2021323 patients
Phase 2Completed
NCT01494753Thea PharmaT2345

Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension

Start: Jun 2008Est. completion: Dec 2008
Phase 2Completed
NCT00595101Bausch + LombPF-03187207

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Start: Dec 2007Est. completion: Jun 2008117 patients
Phase 2Completed
NCT00441883Bausch + LombPF-03187207 and Latanoprost Vehicle

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Start: Mar 2007Est. completion: Jul 2008176 patients
Phase 2Completed
NCT07235592SantenMicroshunt XI

PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group

Start: Mar 2026Est. completion: Apr 2027112 patients
N/ANot Yet Recruiting
NCT04629521AlconCyPass Micro-Stent

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

Start: Dec 2020Est. completion: Apr 202354 patients
N/ACompleted
NCT01841450GlaukosiStent

Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery

Start: Jul 2013Est. completion: Nov 2021
N/AUnknown
NCT00485108Pfizerprednisolone 1%

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty

Start: Jan 2007Est. completion: Dec 2014120 patients
N/ACompleted

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,088 patients
9 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)